2. Search Result
Search Result
Results for "

N6-Methyladenosine

" in MedChemExpress (MCE) Product Catalog:

40

Inhibitors & Agonists

14

Peptides

5

Natural
Products

1

Recombinant Proteins

6

Isotope-Labeled Compounds

1

Antibodies

1

Click Chemistry

9

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N0086
    N6-Methyladenosine
    Maximum Cited Publications
    7 Publications Verification

    6-Methyladenosine; N-Methyladenosine

    		 Influenza Virus Endogenous Metabolite Infection
    N6-Methyladenosine is the most prevalent internal (non-cap) modification present in the messenger RNA (mRNA) of all higher eukaryotes. N6-Methyladenosine can modifies viral RNAs and has antiviral activities.
    N6-Methyladenosine
  • HY-127103
    FB23-2
    Maximum Cited Publications
    26 Publications Verification

    		 Apoptosis Cancer
    FB23-2 is a potent and selective inhibitor of mRNA N 6-methyladenosine (m 6A) demethylase FTO, with an IC50 of 2.6 μM. FB23-2 has anti-proliferation activity. FB23-2 can be used for the research of acute myeloid leukemia (AML) .
    FB23-2
  • HY-134124
    Glutathione ethyl ester

    		Reactive Oxygen Species (ROS) Metabolic Disease
    Glutathione ethyl ester is a cell-permeable GSH donor and provides an efficient supply of GSH to the oocyte. Glutathione ethyl ester shows positive effect on the in vitro production of embryos by enhancement of the antioxidative defense .
    Glutathione ethyl ester
  • HY-137187
    FB23
    2 Publications Verification

    		 Fat Mass and Obesity-associated Protein (FTO) Cancer
    FB23 is a potent and selective FTO demethylase inhibitor with an IC50 of 60 nM. FB23 directly binds to FTO and selectively inhibits FTO's mRNA N 6-methyladenosine (m6A) demethylase activity .
    FB23
  • HY-111926
    N6-Methyladenosine 5'-monophosphate disodium salt
    3 Publications Verification

    		 Biochemical Assay Reagents Others
    N6-Methyladenosine 5'-monophosphate disodium salt is an N6-methyladenosine derivative and also the phosphorylated form of N 6-methyladenosine. N6-Methyladenosine 5'-monophosphate disodium salt serves as an elution reagent for m6A-modified RNA in MeRIP assays .
    N6-Methyladenosine 5'-monophosphate disodium salt
  • HY-P10272
    Rusfertide

    PTG-300

    		 Ferroportin Others
    Rusfertide is a peptide mimetic of natural hepcidin, which targets and degrades ferroportin, reduces serum iron and transferrin-saturation, and thus regulates the production of red blood cells. Rusfertide ameliorates the polycythemia vera, β-thalassemia and hereditary hemochromatosis .
    Rusfertide
  • HY-A0248A
    Polymyxin B1
    1 Publications Verification

    		 Bacterial Infection
    Polymyxin B1 is a potent antimicrobial lipopeptide first derived from Bacilus polymyxa. Polymyxin B1 is the major component in Polymyxin B (HY-A0248). Polymyxin B1 can induce lysis of bacterial cells through interaction with their membranes. Polymyxin B1 has the potential for multidrug-resistant Gram-negative bacterial infections treatment .
    Polymyxin B1
  • HY-N0086R
    N6-Methyladenosine (Standard)
    1 Publications Verification

    6-Methyladenosine (Standard); N-Methyladenosine (Standard)

    		 Endogenous Metabolite Influenza Virus Reference Standards Infection
    N6-Methyladenosine (Standard) is the analytical standard of N6-Methyladenosine. This product is intended for research and analytical applications. N6-Methyladenosine is the most prevalent internal (non-cap) modification present in the messenger RNA (mRNA) of all higher eukaryotes. N6-Methyladenosine can modifies viral RNAs and has antiviral activities. In Vitro: N6-methyladenosine (m6A) is selectively recognized by the human YTH domain family 2 (YTHDF2) protein to regulate mRNA degradation. N6-methyladenosine (m6A), a prevalent internal modification in the messenger RNA of all eukaryotes, is post-transcriptionally installed by m6A methyltransferase (e.g., MT-A70) within the consensus sequence of G(m6A)C (70%) or A(m6A)C (30%). N6-methyladenosine (m6A)-containing RNAs are greatly enriched in the YTHDF-bound portion and diminished in the flow-through portion . N6-methyladenosine (m6A), the most abundant internal RNA modification, functions in diverse biological processes, including regulation of embryonic stem cell self-renewal and differentiation. N6-methyladenosine (m6A) is a large protein complex, consisting in part of methyltransferase-like 3 (METTL3) and methyltransferase-like 14 (METTL14) catalytic subunits .
    N6-Methyladenosine (Standard)
  • HY-155489
    DDO-2728
    2 Publications Verification

    		 Anaplastic lymphoma kinase (ALK) Apoptosis Cancer
    DDO-2728 (compound 19) is a selective AlkB homologue 5 (ALKBH5) inhibitor with an IC50 of 2.97 μM. DDO-2728 increases the abundance of N 6 methyladenosine (m 6A) modifications, inducing cell apoptosis and cycle arrest. DDO-2728 suppresses tumor growth in the MV4 11 xenograft model with favorable safety profile, shows the potential of targeting ALKBH5 in cancer research .
    DDO-2728
  • HY-N0086S
    N6-Methyladenosine-d3

    6-Methyladenosine-d3; N-Methyladenosine-d3

    		 Isotope-Labeled Compounds Influenza Virus Endogenous Metabolite Infection
    N6-Methyladenosine-d3 (6-Methyladenosine-d3; N-Methyladenosine-d3) is a deuterium labeled N6-Methyladenosine (HY-N0086). N6-Methyladenosine is the most prevalent internal (non-cap) modification present in the messenger RNA (mRNA) of all higher eukaryotes. N6-Methyladenosine can modifies viral RNAs and has antiviral activities.
    N6-Methyladenosine-d3
  • HY-P1108A
    Astressin 2B TFA
    1 Publications Verification

    		 CRFR Neurological Disease Inflammation/Immunology
    Astressin 2B TFA is a blood-brain barrier-impermeable, highly selective CRFR2 antagonist (rCRFR2, IC50=0.57 nM). Astressin 2B TFA blocks the protective effects mediated by CRFR2, thereby exacerbating indomethacin (HY-14397)-induced hemorrhagic intestinal injury in rats. Astressin 2B TFA reverses the protective effects of Urocortin 1 against intestinal hypermotility, bacterial invasion and upregulation of inflammatory mediators. Astressin 2B TFA also blocks the anxiogenic effect of Urocortin 2 and attenuates stress-induced anxiety-related behaviors. In the Clostridioides difficile toxin A (C. difficile toxin A)-mediated enteritis model, Astressin 2B TFA mimics the phenotype of CRFR2-deficient mice, significantly exacerbating intestinal epithelial damage, edema, neutrophil migration and the expression of multiple proinflammatory cytokines. Astressin 2B TFA is an important tool molecule for investigating the intestinal protective mechanisms of CRFR2 [6] .
    Astressin 2B TFA
  • HY-P1108
    Astressin 2B
    1 Publications Verification

    		 CRFR Neurological Disease Inflammation/Immunology
    Astressin 2B is a blood-brain barrier-impermeable, highly selective CRFR2 antagonist (rCRFR2, IC50=0.57 nM). Astressin 2B blocks the protective effects mediated by CRFR2, thereby exacerbating indomethacin (HY-14397)-induced hemorrhagic intestinal injury in rats. Astressin 2B reverses the protective effects of Urocortin 1 against intestinal hypermotility, bacterial invasion and upregulation of inflammatory mediators. Astressin 2B also blocks the anxiogenic effect of Urocortin 2 and attenuates stress-induced anxiety-related behaviors. In the Clostridioides difficile toxin A (C. difficile toxin A)-mediated enteritis model, Astressin 2B mimics the phenotype of CRFR2-deficient mice, significantly exacerbating intestinal epithelial damage, edema, neutrophil migration and the expression of multiple proinflammatory cytokines. Astressin 2B is an important tool molecule for investigating the intestinal protective mechanisms of CRFR2 [6] .
    Astressin 2B
  • HY-174979
    Dac590

    		Fat Mass and Obesity-associated Protein (FTO) Apoptosis Inflammation/Immunology Cancer
    Dac590 is an orally active and selective obesity-associated protein (FTO) inhibitor with an IC50 of 6.06 nM. Dac590 shows highly selective over ALKBH5 and ALKBH3. Dac590 suppresses oncogenic FTO signaling, induces myeloid differentiation, G1-phase cell cycle arrest, and apoptosis in acute myeloid leukemia (AML) cells. Dac590 inhibits xenograft tumor growth and prolongs survival in acute myeloid leukemia mouse models with no observed toxicity. Dac590 can be used for the research of AML .
    Dac590
  • HY-N0086S2
    N6-Methyladenosine-13C4

    6-Methyladenosine-13C4; N-Methyladenosine-13C4

    		 Isotope-Labeled Compounds Influenza Virus Endogenous Metabolite Infection
    N6-Methyladenosine- 13C4 (6-Methyladenosine- 13C4; N-Methyladenosine- 13C4) is 13C-labeled N6-Methyladenosine (HY-N0086). N6-Methyladenosine is the most prevalent internal (non-cap) modification present in the messenger RNA (mRNA) of all higher eukaryotes. N6-Methyladenosine can modifies viral RNAs and has antiviral activities.
    N6-Methyladenosine-13C4
  • HY-151106
    FTO-IN-8

    		Fat Mass and Obesity-associated Protein (FTO) Cancer
    FTO-IN-8 (FTO-43) is a N6-methyladenosine demethylase (FTO) (fat mass- and obesity-associated protein) inhibitor with the IC50 value of 5.5 μM. FTO-IN-8 has anti-cancer cell proliferative activity .
    FTO-IN-8
  • HY-168878
    EP652

    		METTL3 Cancer
    EP652 is a METTL3 inhibitor and antitumor agent with IC50 values of 2 nM, <10 nM, and 37 nM in SPA, intracellular, and ATPlite assays, respectively. EP652 exhibits high selectivity against 40 other methyltransferases and FTO, and possesses favorable pharmacokinetic parameters. EP652 reduces intracellular N 6-methyladenosine (m 6A) levels in mRNA. EP652 inhibits tumor growth and progression of both hematologic malignancies and solid tumors. EP652 can be used for the research of acute myeloid leukemia, ovarian cancer, non-small cell lung cancer, and hypopharyngeal squamous cell carcinoma .
    EP652
  • HY-N0086S1
    N6-Methyladenosine-13C

    6-Methyladenosine-13C; N-Methyladenosine-13C

    		 Isotope-Labeled Compounds Others
    N6-Methyladenosine- 13C is the 13C labeled isotope of N6-Methyladenosine .
    N6-Methyladenosine-13C
  • HY-159604
    METTL3-IN-9

    		METTL3 Cancer
    METTL3-IN-9 (compound C3) is an inhibitor of methyltransferase-like METTL3, an RNA methyltransferase that catalyzes the N6-methyladenosine (m6A) modification of mRNA in eukaryotic cells .
    METTL3-IN-9
  • HY-152699
    N6-Methyladenosine N1-oxide

    		Nucleoside Antimetabolite/Analog Others
    N6-Methyladenosine N1-oxide is an adenosine analogue. Adenosine analogs mostly act as smooth muscle vasodilators and have also been shown to inhibit cancer progression. The popular products in this series are adenosine phosphate, Acadesine (HY-13417), Clofarabine (HY-A0005), Fludarabine phosphate (HY-B0028) and Vidarabine (HY-B0277) .
    N6-Methyladenosine N1-oxide
  • HY-P10143
    MMP-2/MMP-9 Substrate

    Ac-Pro-Leu-Gly-[(S)-2-mercapto-4-methyl-pentanoyl]-Leu-Gly-OEt

    		 MMP Others
    MMP-2/MMP-9 Substrate (Ac-Pro-Leu-Gly-[(S)-2-mercapto-4-methyl-pentanoyl]-Leu-Gly-OEt) is a synthetic chromogenic polypeptide substrate whose core structure mimics the cleavage sites of MMP-2 and MMP-9 (gelatinase A and B) in collagen. After being hydrolyzed by collagenase, MMP-2/MMP-9 Substrate reacts with 4,4'-dithiodipyridine or Ellman's Reagent via its thiol fragment to produce a product with ultraviolet absorption properties .
    MMP-2/MMP-9 Substrate
  • HY-A0248AS
    Polymyxin B1-d7 TFA

    		Isotope-Labeled Compounds Bacterial Infection
    Polymyxin B1-d7 TFA is the deuterium labeled Polymyxin B1 TFA (HY-A0248A). Polymyxin B1 is a potent antimicrobial lipopeptide first derived from Bacilus polymyxa. Polymyxin B1 is the major component in Polymyxin B (HY-A0248). Polymyxin B1 can induce lysis of bacterial cells through interaction with their membranes. Polymyxin B1 has the potential for multidrug-resistant Gram-negative bacterial infections treatment .
    Polymyxin B1-d7 TFA
  • HY-131871
    Ethyl LipotF

    		Fat Mass and Obesity-associated Protein (FTO) Cancer
    Ethyl LipotF is a selective FTO inhibitor that significant increases modified N6-methyladenosine (m6A) levels in HeLa cells in a concentration-dependent manner .
    Ethyl LipotF
  • HY-P10563
    Noraramtide

    BHV-1100

    		 CD38 Cancer
    Noraramtide (BHV-1100) is an antibody recruitment molecule. Noraramtide can specifically bind to CD38 molecules to recruit natural killer (NK) cells. Noraramtide enhances the ability of NK cells to kill tumor cells through antibody-dependent cellular cytotoxicity (ADCC). This mechanism allows NK cells to more effectively recognize and eliminate tumor cells while avoiding mutual killing between NK cells. Noraramtide can be used for the study of autologous cancer immunity .
    Noraramtide
  • HY-170668
    DDO-02267

    		Anaplastic lymphoma kinase (ALK) Fat Mass and Obesity-associated Protein (FTO) Cancer
    DDO-02267 is a selective and lysine-targeting covalent inhibitor of ALKBH5, with an IC50 value of 0.49 μM. DDO-02267 increases N 6-methyladenosine (m 6A) levels and targets the ALKBH5-AXL signaling axis. DDO-02267 can serve as a probe for investigating the biological function of mRNA demethylase .
    DDO-02267
  • HY-N0086S3
    N6-Methyladenosine-13C3

    6-Methyladenosine-13C3; N-Methyladenosine-13C3

    		 Isotope-Labeled Compounds Influenza Virus Endogenous Metabolite Infection
    N6-Methyladenosine- 13C3 (6-Methyladenosine- 13C3) is 13C-labeled N6-Methyladenosine (HY-N0086). N6-Methyladenosine is the most prevalent internal (non-cap) modification present in the messenger RNA (mRNA) of all higher eukaryotes. N6-Methyladenosine can modifies viral RNAs and has antiviral activities .
    N6-Methyladenosine-13C3
  • HY-P3066
    SKF 100398

    d(CH2)5Tyr(Et)VAVP

    		 Vasopressin Receptor Metabolic Disease
    SKF 100398 (d(CH2)5Tyr(Et)VAVP), an arginine vasopressin (AVP) analogue, is a specific antagonist of the antidiuretic effect of exogenous and endogenous AVP .
    SKF 100398
  • HY-152590
    3’-Deoxy-N6-methyladenosine

    		Nucleoside Antimetabolite/Analog Cancer
    3’-Deoxy-N6-methyladenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
    3’-Deoxy-N6-methyladenosine
  • HY-152307
    2-Chloro-N6-methyladenosine

    		Nucleoside Antimetabolite/Analog Cancer
    2-Chloro-N6-methyladenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
    2-Chloro-N6-methyladenosine
  • HY-152425
    2-Methylamino-N6-methyladenosine

    		Nucleoside Antimetabolite/Analog Others
    2-Methylamino-N6-methyladenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
    2-Methylamino-N6-methyladenosine
  • HY-152315
    3’-Azido-3’-deoxy-N6-methyladenosine

    		Nucleoside Antimetabolite/Analog Others
    3’-Azido-3’-deoxy-N6-methyladenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 3’-Azido-3’-deoxy-N6-methyladenosine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
    3’-Azido-3’-deoxy-N6-methyladenosine
  • HY-152301
    3’-Deoxy-3’-fluoro-N6-methyladenosine

    		Nucleoside Antimetabolite/Analog Others
    3’-Deoxy-3’-fluoro-N6-methyladenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
    3’-Deoxy-3’-fluoro-N6-methyladenosine
  • HY-152553
    4’-C-Methyl-N6-methyladenosine

    		Nucleoside Antimetabolite/Analog Others
    4’-C-Methyl-N6-methyladenosine is an adenosine analogue. Adenosine analogs mostly act as smooth muscle vasodilators and have also been shown to inhibit cancer progression. The popular products in this series are adenosine phosphate, Acadesine (HY-13417), Clofarabine (HY-A0005), Fludarabine phosphate (HY-B0028) and Vidarabine (HY-B0277) .
    4’-C-Methyl-N6-methyladenosine
  • HY-152558
    5’(R)-C-Methyl-N6-methyladenosine

    		Nucleoside Antimetabolite/Analog Others
    5’(R)-C-Methyl-N6-methyladenosine is an adenosine analogue. Adenosine analogs mostly act as smooth muscle vasodilators and have also been shown to inhibit cancer progression. The popular products in this series are adenosine phosphate, Acadesine (HY-13417), Clofarabine (HY-A0005), Fludarabine phosphate (HY-B0028) and Vidarabine (HY-B0277) .
    5’(R)-C-Methyl-N6-methyladenosine
  • HY-152370
    3’-beta-C-Methyl-N6-methyladenosine

    		Nucleoside Antimetabolite/Analog Others
    3’-beta-C-Methyl-N6-methyladenosine is an adenosine analogue. Adenosine analogs mostly act as smooth muscle vasodilators and have also been shown to inhibit cancer progression. The popular products in this series are adenosine phosphate, Acadesine (HY-13417), Clofarabine (HY-A0005), Fludarabine phosphate (HY-B0028) and Vidarabine (HY-B0277) .
    3’-beta-C-Methyl-N6-methyladenosine
  • HY-P10828
    MAPI

    		Virus Protease Infection Inflammation/Immunology
    MAPI is a polypeptide irreversible 3C cysteine protease (SV3CP) inhibitor. MAPI inhibits SV3CP by covalently binding its C-terminal Michael-acceptor extension to the active site thiol of SV3CP Cys 139. MAPI is promising for research of noroviruses infection .
    MAPI
  • HY-179239
    METTL3-IN-12

    		METTL3 Cancer
    METTL3-IN-12 (Compound 15) is a selective METTL3 inhibitor with an IC50 of 50 nM. METTL3-IN-12 exhibits significant anti-proliferative activity in various leukemia cell lines. METTL3-IN-12 can be used for research on leukemia .
    METTL3-IN-12
  • HY-183186
    EP102

    		METTL3 Cytochrome P450 Cancer
    EP102 is an orally active, selective inhibitor of the METTL3/METTL14 complex with an IC50 of 2 nM. EP102 reduces intracellular N6-methyladenosine levels, inhibits cancer cell proliferation, and thereby suppresses tumor growth in mouse models. EP102 is applicable for the research of acute myeloid leukemia, ovarian solid tumors and advanced solid tumors .
    EP102
  • HY-P2592
    Ro 23-7014

    		Cholecystokinin Receptor Others
    Ro 23-7014 is an appetite suppressant. Ro 23-7014 is an analog of cholecystokinin (CCK-7) .
    Ro 23-7014
  • HY-125628
    Kahalalide A

    		Endogenous Metabolite Infection
    Kahalalide A is an anti-mycobacterial compound with antimicrobial activity. Kahalalide A is derived from the marine mollusk Elysia rufescens. Kahalalide A has attracted extensive attention in natural product research due to its potential medicinal value .
    Kahalalide A
  • HY-A0248AS1
    Polymyxin B1-D-Leu-d7 TFA

    		Isotope-Labeled Compounds Bacterial Infection
    Polymyxin B1-D-Leu-d7 TFA is the deuterium labeled Polymyxin B1 (HY-A0248A). Polymyxin B1 is a potent antimicrobial lipopeptide first derived from Bacilus polymyxa. Polymyxin B1 is the major component in Polymyxin B (HY-A0248). Polymyxin B1 can induce lysis of bacterial cells through interaction with their membranes. Polymyxin B1 has the potential for multidrug-resistant Gram-negative bacterial infections treatment .
    Polymyxin B1-D-Leu-d7 TFA

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: